Long non-coding RNAs in head and neck squamous cell carcinoma: Diagnostic biomarkers, targeted therapies, and prognostic roles

2021 ◽  
Vol 902 ◽  
pp. 174114
Author(s):  
Xiang Meng ◽  
Zi-Fei Wang ◽  
Qiu-Yue Lou ◽  
Abigail N. Rankine ◽  
Wan-Xin Zheng ◽  
...  
2018 ◽  
Vol 50 (1) ◽  
pp. 332-341 ◽  
Author(s):  
Guomiao Zhao ◽  
Yaru Fu ◽  
Zhifang Su ◽  
Rongling wu

Background/Aims: Long non-coding RNAs (lncRNAs) act as competing endogenous RNAs (ceRNAs) to compete for microRNAs (miRNAs) in cancer metastasis. Head and neck squamous cell carcinoma (HNSCC) is one of the most common human cancers and rare biomarkers could predict the clinical prognosis of this disease and its therapeutic effect. Methods: Weighted gene co-expression network analysis (WGCNA) was performed to identify differentially expressed mRNAs (DEmRNAs) that might be key genes. GO enrichment and protein–protein interaction (PPI) analyses were performed to identify the principal functions of the DEmRNAs. An lncRNA-miRNA-mRNA network was constructed to understand the regulatory mechanisms in HNSCC. The prognostic signatures of mRNAs, miRNAs, and lncRNAs were determined by Gene Expression Profiling Interactive Analysis (GEPIA) and using Kaplan–Meier survival curves for patients with lung squamous cell carcinoma. Results: We identified 2,023 DEmRNAs, 1,048 differentially expressed lncRNAs (DElncRNAs), and 82 differentially expressed miRNAs (DEmiRNAs). We found that eight DEmRNAs, 53 DElncRNAs, and 16 DEmiRNAs interacted in the ceRNA network. Three ceRNAs (HCG22, LINC00460 and STC2) were significantly correlated with survival. STC2 transcript levels were significantly higher in tumour tissues than in normal tissues, and the STC2 expression was slightly upregulated at different stages of HNSCC. Conclusion: LINC00460, HCG22 and STC2 exhibited aberrant levels of expression and may participate in the pathogenesis of HNSCC.


ISRN Surgery ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Eric J. Yavrouian ◽  
Uttam K. Sinha

Head and neck squamous cell carcinoma (HNSCC) is a devastating tumor of the upper aerodigestive tract with no significant change in treatment modality or improvement in survival over the last several decades. Biomarkers are important biological molecules that can be utilized in tumor detection, prognosis, and as targeted therapies. There are several important biomarkers and potential targets in the forefront, including biomarkers of tumorigenesis, signal transduction molecules, proteins involved in angiogenesis, and oncogenic viruses. The clinical applications of these biomarkers are in various states from in vitro and in vivo models, phase II and III clinical trials, to accepted modes of treatment in patients with HNSCC. Given the potential improvement in prognosis that biomarkers and their targeted therapies may have on the treatment of HNSCC, their investigation is both important and essential.


Oral Diseases ◽  
2017 ◽  
Vol 24 (8) ◽  
pp. 1417-1427 ◽  
Author(s):  
MK Sannigrahi ◽  
R Sharma ◽  
NK Panda ◽  
M Khullar

2016 ◽  
Vol 12 (4) ◽  
pp. 2846-2853 ◽  
Author(s):  
Vicky Yu ◽  
Pranav Singh ◽  
Elham Rahimy ◽  
Hao Zheng ◽  
Selena Z. Kuo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document